MedTrace Logo

Remote Ischemic Preconditioning for Aute Type A Aortic Dissection Surgery

NCT07383909 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1296

Last updated 2026-02-03

No results posted yet for this study

Summary

The goal of this clinical trial is to learn if a technique called remote ischemic preconditioning (RIPC) helps protect organs during emergency surgery for acute type A aortic dissection (ATAAD). The main questions it aims to answer are:

Does RIPC reduce the risk of major complications after surgery, such as heart, brain, or kidney problems?

Is RIPC safe to use during emergency ATAAD surgery?

Researchers will compare the RIPC group to a control group (who will receive a placebo) to see if RIPC can reduce complications after surgery.

Participants will:

Receive either RIPC or a sham intervention during their surgery.

Be monitored for up to 30 days after surgery for complications.

Have follow-up visits at 3 months, 1 year, and then yearly for up to 5 years to track their recovery.

Conditions

  • Aortic Dissection Type A

Interventions

PROCEDURE

Remote ischemic preconditioning (RIPC)

This intervention is a non-invasive organ protection procedure. After induction of general anesthesia, 4 cycles of remote ischemic preconditioning (RIPC) are applied to the upper arm and thigh on the non-arterial cannulation side. Each cycle consists of 5 minutes of cuff inflation (at 200 mmHg, or systolic blood pressure +15 mmHg if systolic blood pressure exceeds 185 mmHg) to induce ischemia, followed by 5 minutes of cuff deflation for reperfusion. To ensure safety, the cuff inflation cycles alternate between the upper arm and thigh. The procedure aims to activate endogenous protective mechanisms, enhancing the tolerance of vital organs to subsequent ischemic injury during surgery.

Sponsors & Collaborators

  • The First Affiliated Hospital of Dalian Medical University

    collaborator OTHER

  • Xiamen Cardiovascular Hospital, Xiamen University

    collaborator OTHER

  • Fujian Medical University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-01-05
Primary Completion
2029-01-31
Completion
2032-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07383909 on ClinicalTrials.gov